Kottil Rammohan

11.9k total citations · 4 hit papers
127 papers, 5.7k citations indexed

About

Kottil Rammohan is a scholar working on Pathology and Forensic Medicine, Neurology and Epidemiology. According to data from OpenAlex, Kottil Rammohan has authored 127 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Pathology and Forensic Medicine, 26 papers in Neurology and 19 papers in Epidemiology. Recurrent topics in Kottil Rammohan's work include Multiple Sclerosis Research Studies (61 papers), Peripheral Neuropathies and Disorders (18 papers) and Semiconductor Quantum Structures and Devices (16 papers). Kottil Rammohan is often cited by papers focused on Multiple Sclerosis Research Studies (61 papers), Peripheral Neuropathies and Disorders (18 papers) and Semiconductor Quantum Structures and Devices (16 papers). Kottil Rammohan collaborates with scholars based in United States, United Kingdom and Germany. Kottil Rammohan's co-authors include Jerry R. Mendell, John T. Kissel, Gavin Giovannoni, Patrick Vermersch, Per Soelberg Sørensen, Peter Rieckmann, Stuart D. Cook, Gıancarlo Comı, Anthony Hamlett and Steven J. Greenberg and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Kottil Rammohan

123 papers receiving 5.5k citations

Hit Papers

A Placebo-Controlled Trial of Ora... 1986 2026 1999 2012 2010 2014 1986 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
    2010 689 citations Gavin Giovannoni, Gıancarlo Comı et al. New England Journal of Medicine profile →
  2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
    2014 664 citations Peter A. Calabresi, Douglas S. Goodin et al. profile →
  3. Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis
    1986 381 citations John T. Kissel, Jerry R. Mendell et al. New England Journal of Medicine profile →
  4. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
    2021 181 citations Amber Salter, Robert J. Fox et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kottil Rammohan United States 34 3.4k 1.5k 1.1k 1.0k 914 127 5.7k
Stuart D. Cook United States 41 2.8k 0.8× 1.5k 1.1× 1.0k 1.0× 634 0.6× 662 0.7× 152 5.6k
Klaus Schmierer United Kingdom 42 4.3k 1.3× 1.8k 1.2× 1.2k 1.1× 908 0.9× 934 1.0× 171 6.9k
Jan Lycke Sweden 43 4.1k 1.2× 1.8k 1.3× 1.3k 1.2× 1.1k 1.1× 876 1.0× 148 6.3k
Anders Svenningsson Sweden 38 3.4k 1.0× 1.7k 1.2× 1.1k 1.1× 862 0.9× 620 0.7× 110 5.4k
Pierre Duquette Canada 42 4.1k 1.2× 1.4k 1.0× 1.0k 1.0× 860 0.9× 1.2k 1.3× 129 7.2k
Elizabeth Fisher United States 41 5.4k 1.6× 2.0k 1.3× 1.2k 1.1× 926 0.9× 1.7k 1.9× 108 7.2k
Ernst‐Wilhelm Radue Switzerland 39 4.2k 1.2× 1.7k 1.2× 1.3k 1.2× 1.5k 1.5× 1.0k 1.1× 117 7.3k
Paolo Gallo Italy 48 4.8k 1.4× 2.2k 1.5× 940 0.9× 945 0.9× 1.3k 1.5× 182 7.6k
Kevin C. O’Connor United States 48 2.4k 0.7× 1.8k 1.2× 785 0.7× 1.5k 1.5× 669 0.7× 154 7.8k
Tobias Derfuß Switzerland 41 3.2k 0.9× 1.7k 1.1× 1.1k 1.0× 1.4k 1.4× 783 0.9× 149 6.6k

Countries citing papers authored by Kottil Rammohan

Since Specialization
Citations

This map shows the geographic impact of Kottil Rammohan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kottil Rammohan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kottil Rammohan more than expected).

Fields of papers citing papers by Kottil Rammohan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kottil Rammohan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kottil Rammohan. The network helps show where Kottil Rammohan may publish in the future.

Co-authorship network of co-authors of Kottil Rammohan

This figure shows the co-authorship network connecting the top 25 collaborators of Kottil Rammohan. A scholar is included among the top collaborators of Kottil Rammohan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kottil Rammohan. Kottil Rammohan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ontaneda, Daniel, Tanuja Chitnis, Kottil Rammohan, & Ahmed Z. Obeidat. (2023). Identification and management of subclinical disease activity in early multiple sclerosis: a review. Journal of Neurology. 271(4). 1497–1514. 18 indexed citations
2.
Giovannoni, Gavin, Alexey Boyко, Jorge Correale, et al.. (2023). Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple Sclerosis Journal. 29(6). 719–730. 23 indexed citations
3.
Stefano, Nicola De, Maria Pia Sormani, Gavin Giovannoni, et al.. (2021). Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal. 28(1). 111–120. 21 indexed citations
4.
5.
6.
Newsome, Scott D., Anne H. Cross, Robert J. Fox, et al.. (2021). COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America. Neurology Neuroimmunology & Neuroinflammation. 8(5). 12 indexed citations
7.
Salter, Amber, June Halper, Bruce F. Bebo, et al.. (2020). Covims registry: clinical characterization of SARS-COV-2 infected multiple sclerosis patients in north america. Multiple Sclerosis Journal. 26. 97–97. 3 indexed citations
8.
Giovannoni, Gavin, Per Soelberg Sørensen, Stuart D. Cook, et al.. (2017). Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal. 24(12). 1594–1604. 243 indexed citations
9.
Giovannoni, Gavin, Kottil Rammohan, Stuart D. Cook, et al.. (2017). Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351). Neurology. 88(16_supplement). 2 indexed citations
10.
Ortega, Melissa, et al.. (2016). Moderate Caffeine Intake and Verbal Memory in Multiple Sclerosis: A Pilot Study. 6(3). 134–138. 1 indexed citations
11.
12.
Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. mediaTUM (Technical University of Munich). 36 indexed citations
13.
Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017). Neurology. 84(14_supplement). 2 indexed citations
14.
Vollmer, Timothy, Douglas Jeffery, Douglas G. Goodin, et al.. (2013). Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165). Neurology. 80(7_supplement). 7 indexed citations
15.
Goodin, Douglas S., Douglas Jeffery, Ludwig Kappos, et al.. (2013). Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102). Neurology. 80(7_supplement). 4 indexed citations
16.
Ali, Shehzad, Noman Paracha, Stuart D. Cook, et al.. (2011). Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical Drug Investigation. 32(1). 15–27. 11 indexed citations
17.
Basso, Michele, et al.. (1997). Screening for cognitive dysfunction in multiple sclerosis. American Journal of Ophthalmology. 123(2). 278–279. 2 indexed citations
18.
Huber, Steven J., et al.. (1992). Magnetic resonance imaging correlates of executive function impairments in multiple sclerosis. 5(1). 33–36. 9 indexed citations
19.
Kissel, John T., Jerry R. Mendell, & Kottil Rammohan. (1986). Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis. New England Journal of Medicine. 314(6). 329–334. 381 indexed citations breakdown →
20.
Rammohan, Kottil, M. Dubois-Dalcq, Bernard Rentier, & Joan Paul. (1983). Experimental models to study measles virus persistence in the nervous system. Open Repository and Bibliography (University of Liège). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart D. Cook Breakdown of academic impact, for papers by Klaus Schmierer Breakdown of academic impact, for papers by Jan Lycke Breakdown of academic impact, for papers by Anders Svenningsson Breakdown of academic impact, for papers by Pierre Duquette Breakdown of academic impact, for papers by Elizabeth Fisher Breakdown of academic impact, for papers by Ernst‐Wilhelm Radue Breakdown of academic impact, for papers by Paolo Gallo Breakdown of academic impact, for papers by Kevin C. O’Connor Breakdown of academic impact, for papers by Tobias Derfuß
Rankless by CCL
2026